Results 111 to 120 of about 725,921 (266)

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

Vascular Health and Risk Management, 2007
Baptist GallwitzDept. Medicine IV, Eberhard Karls University, Tuebingen, GermanyAbstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 ...
Baptist Gallwitz
doaj  

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression

, 2014
The standard of chemotherapy regimens for advanced or metastatic gastric cancer and the clinical outcome were heterogeneous in Asian versus non-Asian countries.
Hsu, Chiun;Shen, Ying-Chun;Cheng, Chia-Chi;Cheng, Ann-Lii;Hu, Fu-Chang;Yeh, Kun-Huei, 鄭安理 ;許駿 ;葉坤輝   +1 more
core   +1 more source

Acute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP‐1 and Glycaemic Responses in Post‐Bariatric Hypoglycaemia: A Randomised Crossover Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To evaluate the acute effects of acarbose and canagliflozin, alone and in combination, on postprandial total GLP‐1 and glycaemic responses during a mixed meal test in adults with post‐bariatric hypoglycaemia (PBH). Materials and Methods This single‐centre, randomised, four‐period crossover physiological study included 12 adults with PBH ...
Wei Yang, Anna Kowalka, Lara Jimenez‐Pacheco, Veronica Greener, Kleopatra Alexiadou, Ahmed Ahmed, Julia Kenkre, Chioma Izzi‐Engbeaya, Saira Hameed, Harvinder Chahal, Bernard Khoo, Tricia M.‐M. Tan   +11 more
wiley   +1 more source

Perceived Stress, Hair Cortisol and Hair Cortisone in Relation to Appetite-Regulating Hormones in Patients with Obesity

Obesity Facts
Introduction: Stress predicts unhealthy eating, obesity, and metabolic deterioration, likely mediated by altered levels of appetite- and metabolism-regulating hormones.
Susanne Kuckuck, Robin Lengton, Renate E.H. Meeusen, Eline S. van der Valk, Manon H.J. Hillegers, Brenda W.J.H. Penninx, Maryam Kavousi, Jenny A. Visser, Mariëtte R. Boon, Sjoerd A.A. van den Berg, Elisabeth F.C. van Rossum   +10 more
doaj   +1 more source

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States.

PLoS ONE, 2017
Inflammation is increasingly thought to be associated with diabetes; however, only a few inflammation markers have been assessed concurrently in relation to history of diabetes. In the most comprehensive evaluation of inflammation markers and diabetes to
Alison L Van Dyke, Krystle A Lang Kuhs, Meredith S Shiels, Jill Koshiol, Britton Trabert, Erikka Loftfield, Mark P Purdue, Nicolas Wentzensen, Ruth M Pfeiffer, Hormuzd A Katki, Allan Hildesheim, Troy J Kemp, Ligia A Pinto, Anil K Chaturvedi, Mahboobeh Safaeian   +14 more
doaj   +1 more source

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

, 2003
AIMS/HYPOTHESIS: In the isolated perfused pancreas, gastric inhibitory polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose concentrations, but in healthy humans no glucagonotropic effect of GIP has yet been reported. Therefore,
Nauck, M A, Meier, J J, Holst, Jens Juul, Deacon, C F, Siepmann, N., Schmidt, W.E., Gallwitz, B, Siepmann, N, Deacon, C.F., Meier, J.J., Nauck, M.A., Gallwitz, N., Schmidt, W E   +12 more
core   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications

Journal of Internal Medicine, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists provide benefits in weight reduction, glycaemic control in Type 2 diabetes, and cardiovascular and renal outcomes. Their widespread use has given rise to concerns regarding rare but potentially serious adverse events.
Peter Ueda
wiley   +1 more source